Merrimack
Investor Relations Department
One Kendall Square
Suite B7201
Cambridge, MA 02139
United States

Visit IR website
Sign-up for Email alerts

NASDAQ: MACK	
Last Trade:	3.04
Trade Time:	4:00 PM ET Mar 29, 2017
Change:	0.03 (+0.997%)
Day Range	2.98 - 3.05
52-Week Range	2.83 - 9.02
Volume	1,963,760

Stock information is provided by eSignal, stock charts provided by EDGAR Online. Stock data is delayed approximately 20 minutes.

Company Profile

Merrimack is a biopharmaceutical company based in Cambridge, Massachusetts that is outthinking cancer to ensure that patients and their families live fulfilling lives. Our mission is to transform cancer care through the smart design and development of targeted solutions based on the deep understanding of cancer pathways and biological markers. All of our product candidates, including three in clinical studies and several others in preclinical development, fit into our three -pronged strategy of 1) understanding the biological problems we are trying to solve, 2) designing specific solution... (more)

Stock Performance



Press Releases [View all]

Mar 27, 2017
Merrimack to Present at the 2017 American Association for Cancer Research Annual Meeting

Mar 23, 2017
Merrimack Initiates Phase 1 Study of MM-310 in Solid Tumors

Mar 1, 2017
Merrimack Reports Fourth Quarter and Full-Year 2016 Financial Results

Feb 22, 2017
Merrimack Announces Timing of Fourth Quarter 2016 Investor Conference Call

Jan 18, 2017
Merrimack Names Richard Peters, M.D., Ph.D., as President and CEO

Financials [View all]

Mar 1, 2017
Annual Report (10-K)